Despite the notion that Bax and Bak are indispensable for apoptosis, 12 the molecular cascade that mediates their activation is presently a matter of debate. New developments have shed light on the interaction between members of the Bcl-2 family. Specifically, the pivotal prosurvival Mcl-1 interacts, among others, with Noxa, Bim, Puma and Bak in model cell lines. 13, 14 These findings may be relevant in connection with our observation of elevated expression of Noxa in B-CLL, 6 and in light of the above-mentioned concept of 'oncogene addiction. ' In the present study, we investigated the molecular mechanism underlying apoptosis elicited by seliciclib in B-CLL, with emphasis on protein interactions between Bcl-2 family members. We show for the first time that Mcl-1 is associated with Noxa in primary leukemic cells and that Noxa is required to trigger the mitochondrial apoptosis pathway upon seliciclib treatment. Furthermore, despite rapid proteasome-dependent degradation of Mcl-1 (within 4 h), Bax/Bak activation and apoptosis are substantially delayed (16-20 h) . During this time, Bim and Bax become associated with Bcl-2 and these proteins eventually translocate to a mitochondriarich insoluble fraction. Our data suggest that in the absence of Mcl-1, the remaining apoptosis neutralizing capacity of Bcl-2 is gradually overwhelmed, resulting in Bax/Bak multimerization and pore formation in the mitochondria.
Results
Seliciclib induces apoptosis and rapid proteasomedependent degradation of Mcl-1. The effect of seliciclib on cell viability was investigated in 20 B-CLL samples. B-CLL cells were 490% pure as determined by flow cytometry. Consistent with previous reports, 15 in vitro culture of B-CLL cells was accompanied by a moderate spontaneous increase in apoptosis. Increasing doses (10, 25 and 50 mM) of seliciclib resulted in dose-dependent increase of apoptosis ( Figure 1a ). In comparison, cells treated with a high dose of fludarabine (100 mM) showed a lower level of apoptosis at 24 h of treatment (Figure 1a ), but this increased over time (data not shown). IgV H mutated and unmutated B-CLL patients (n ¼ 8 versus n ¼ 12) showed no difference in apoptosis induction by seliciclib (data not shown).
Seliciclib was reported to result in rapid proteasomal breakdown of Mcl-1 protein. 11 Mcl-1 is also described as a substrate for caspase-mediated degradation. 16 We tested which of these pathways predominates in B-CLL. Seliciclib was applied in combination with zVAD-fmk and the proteasome inhibitors MG132 and bortezomib. As shown in Figure 1b , the degradation of Mcl-1 in B-CLL cells was at best partially affected by zVAD-fmk (lane 2 versus lane 3). In contrast, the proteasome inhibitors MG132 and bortezomib almost fully prevented Mcl-1 degradation (lane 2 versus lanes 4 and 5). Thus, in B-CLL cells Mcl-1 is largely degraded already 4 h after addition of seliciclib, predominantly via the proteasome.
In B-CLL, Mcl-1 associates with Noxa and Bim but not with Bak. Prior studies in model cell lines indicate that Mcl-1 selectively interacts with Bim, Bak, Puma and Noxa, whereas Noxa has a strong preference for Mcl-1 and possibly Bfl-1. 13, 14, 17 . In primary B-CLL cells, the majority of Noxa protein was associated with Mcl-1 ( Figure 2 , compare IP with cleared lysate lanes). As also reported for normal tonsil B cells, 18 Bim was clearly but not exclusively associated with Mcl-1. Cells were then analyzed after 2 h of seliciclib treatment, that is, before extensive degradation of Mcl-1 and zVAD-fmk or MG132 were added to block caspases or the proteasome. Rapid dissociation of Bim from Mcl-1 could be observed, while Noxa was still largely bound ( Figure 2 , left panels).
Previous studies in HeLa cells indicated that Mcl-1 directly sequesters Noxa, Bim and Bak, and upon UV treatment, Bak is displaced by Noxa. 19 In B-CLL cells, Mcl-1 was associated with Noxa and Bim, but we consistently could not detect association of Mcl-1 with Bak, irrespective of seliciclib treatment, although Bak was present in CLL lysates (Figure 2 Noxa-deficient cells exhibit resistance to seliciclibinduced apoptosis. To test whether the association between Noxa and Mcl-1 was reflected at a functional level, the endogenous levels of Noxa and Mcl-1 were manipulated in model systems via RNAi and overexpression. A significant reduction of Noxa in Ramos FSA cells was achieved with two different siRNA sequences (N7 and N8; Figure 3Aa ). Functionally, Noxa RNAi conferred a significant resistance to apoptosis induced by seliciclib compared to the mock-transduced cells ( Figure 3B ), which correlated with the knockdown in Noxa protein. These data were confirmed in the Mec-1 cell line ( Figure 3C ), originally derived from a B-CLL patient, and the Jurkat T cell line 20 ( Figure 3D ). In contrast, upon several other death stimuli like fludarabine, staurosporine, CD95 and BCR stimulation, no significant effect of reduced Noxa levels was observed ( Figure 3B ). Conversely, increased Mcl-1 levels (Figure 3Ab ) conferred resistance to seliciclib, but also to several other apoptotic stimuli ( Figure 3E ). In agreement with the Mcl-1 association studies in B-CLL presented in Figure 2 , knockdown of Bim also resulted in increased resistance against seliciclib. As might be expected from its broader interaction range compared to Noxa, Bim knockdown conferred resistance against diverse apoptotic stimuli, among which was taxol, in agreement with earlier studies. 21 In conclusion, these data indicate that Noxa functions specifically in case of Mcl-1 degradation, such as after seliciclib treatment.
Delay
in Bax/Bak activation upon seliciclib treatment. Most forms of apoptosis ultimately require activation of Bax and/or Bak, which can be monitored with conformation-specific antibodies.
22 Surprisingly, we observed that at 4 h after seliciclib treatment, when Mcl-1 degradation was almost complete as shown above, activation of Bax/Bak was still minimal (see Figure 4, As Bax is translocated to the membrane fraction during seliciclib-induced apoptosis, we assessed its subcellular distribution using confocal microscopy. Figure 5c shows that Bax is localized throughout the cytoplasm in untreated B-CLL cells. Following 16 h seliciclib treatment ( þ pretreatment with zVAD), Bax showed a punctate distribution and colocalization with the mitochondria, suggesting that Bax multimerizes at the mitochondria.
Bcl-2 confers a temporary block to seliciclib-induced apoptosis. To directly determine the role of Bcl-2 in the delayed onset of seliciclib-induced apoptosis, we used a Ramos model cell line overexpressing Bcl-2. 23 In Figures 6c and d) . The effect of seliciclib on Mcl-1 produced from a recombinant vector may be less than on the endogenous transcript. However, the recently described phosphorylation of Mcl-1 at Ser64 which enhances its apoptotic activity is apparently also prevented by seliciclib, 24 therefore a complete block of seliciclibinduced apoptosis of overexpressed Mcl-1 is not expected. Together, our data indicate that manipulation of individual Bcl-2 family members is insufficient to warrant full protection to seliciclib, which suggest they are subject to an intricate functional interplay.
Discussion
In hematological cells, the primary apoptotic trigger ascribed to the novel CDK inhibitor seliciclib is a rapid decrease in Mcl-1 levels independent of p53 function. 9, 11 This is of clinical importance in view of the poor prognosis of B-CLL with functional deficiency in the p53 pathway 25 and the outgrowth of p53-deficient clones during treatment.
1 Furthermore, there is broad interest in the exact mechanism of action of the various Bcl-2 family members, as it has become clear that their protective function can be targeted also directly by pharmacological compounds. 26 However, in the absence of a functional link to Bax and/or Bak activation, drug-induced Mcl-1 decrease is in itself not sufficient to explain cell death. Our findings emphasize two new aspects in the chain of events triggered in B-CLL cells upon seliciclib treatment and Mcl-1 degradation. We found previously that the BH3-only protein Noxa is expressed at high levels in B-CLL, 6 and here we establish that the molecular effects of seliciclib rely on Noxa. Secondly, subsequent to Mcl-1 degradation, we observed a gradual deterioration of the protection afforded by Bcl-2, which was most probably caused by liberated Bim.
Biochemical studies have shown that distinct BH3-only proteins have differential binding affinities to prosurvival Bcl-2 proteins. 13, 14, 27 Reportedly, Noxa has a strong preference for binding to Mcl-1 which we confirm here in primary B-CLL cells (Figure 2 ). At present, the precise role of Noxa is not entirely Although Noxa levels are 5-10 times higher in B-CLL than in normal B cells, 6 this is apparently in itself not a direct trigger for apoptosis, which fits well with the current view of its function as an indirect apoptosis mediator. 13, 14 The available evidence indicates that Noxa acts by displacing proapoptotic Bcl-2 members from Mcl-1. 19, 27 We have studied potential involvement of two proapoptotic candidates Bak and Bim in seliciclib-mediated apoptosis in B-CLL. In agreement with studies in HeLa cells, 19 we found that Noxa can liberate Bak from Mcl-1 in leukemic cell lines (data not shown). However, we consistently could not detect Mcl-1 associated with Bak in primary B-CLL cells. Instead, we observed that the level of Bim associated with Mcl-1 rapidly declined upon seliciclib treatment, while Noxa remained bound (Figure 2 ). This is consistent with the differential binding affinities among the BH3-only members reported by others. 13, 17 Once liberated from Mcl-1, Bim is reportedly capable of directly activating Bax and/or Bak. 14, 27 Direct association between Bax or Bak with purported direct BH3-only activators such as Bid and Bim in model systems has been described. 28, 29 Yet, direct association of endogenous proteins under physiological conditions is difficult to observe. We were also unable in various co-immunoprecipitation approaches to find Bim complexed with Bax or Bak in early or late apoptotic B-CLL cells. The aspect of direct versus indirect activation of Bax (or Bak) by BH3-only members such as Bim is currently the subject of intense research and debate. 27, 30, 31 Although it is in fact still unknown what actually causes transition of cytosolic Bax, 32 its activation is known to result in multimerization and pore formation in mitochondria. 33 Therefore, we looked for shifts from soluble to insoluble fraction upon apoptosis initiation, and could observe transition of both Bim and Bax to the mitochondria-rich insoluble cell fraction ( Figure 5 interaction between Bim and Bax is presumably short-lived, and/or induces rapid multimerization and insertion of Bax in the mitochondrial membrane. At this point, the interacting proteins become insoluble and can no longer be detected by standard co-immunoprecipitation approaches. This possible sequence of events upon seliciclib treatment of B-CLL cells is schematically depicted in Figure 7 .
The proposed sequence of events from Mcl-1 degradation, Noxa-dependent Bim displacement and liberation, and finally Bax activation is compatible with recent data and interpretations concerning the hierarchical involvement of BH3-only members in initiation of the mitochondrial apoptosis pathway. 13, 27 Moreover, a functional linkage between Noxa and Bim was very recently reported in cell lines. 34 During the period between Mcl-1 degradation and eventual Bax/Bak activation in B-CLL cells, there were no significant changes in gene transcription of Bcl-2 family members (data not shown). The available data suggest that after Mcl-1 degradation, Bcl-2 is temporarily capable of withstanding the proapoptotic action of Bim and Bax, but is progressively overwhelmed. In support of this, overexpression of Bcl-2 in a model system could indeed delay but not prevent apoptosis induced by seliciclib treatment (Figure 6 ). The gradual undermining of Bcl-2 function could either be a direct effect of seliciclib by an as-yet unknown pathway, or indirectly result from shifts in the distribution of and interactions between Bcl-2 family members.
The findings reported here agree with and complement recent findings concerning the mechanism of action of the BH3-mimetic ABT-737. 35, 36 This compound can counteract the protective function of Bcl-2, Bcl-XL and Bcl-w and has potential as a cancer therapeutic. 26 Cells overexpressing Mcl-1 are however resistant to ABT-737, and strategies to target Mcl-1 levels enhance its efficacy. 35, 36 On the basis of our findings with B-CLL cells reported here and elsewhere, 37 both direct targeting of Mcl-1 by drugs such as seliciclib and indirect targeting by means of bortezomib to increase Noxa levels, may be a promising combination with ABT-737 or similar compounds. Indeed, it has been shown very recently that seliciclib treatment dramatically increased ABT-737 lethality in human leukemia cell lines. 38 Overall, the functional crosstalk between Bcl-2 family members suggest that the 'addiction' of leukemic cells to overexpression of antiapoptosis proteins such as Bcl-2 and Mcl-1 could be specifically targeted and exploited in a therapeutic setting. The B-CLL cell line Mec-1 40 was a kind gift of Dr. Caligaris-Cappio (Milano, Italy). Mock and two Noxa siRNA sequences (N7 or N8) were retrovirally transduced into the Ramos FSA, Mec-1 and J16 cell lines as described previously. 20 Furthermore, siRNA targeting Bim (pSuper-Bim) was kindly provided by Andreas Villunger (Biocenter, Innsbrück, Austria) and subcloned in the EcoRI/Xho sites of pRetroSuper. After retroviral transduction of J16 cell line, the B18 and B22 subclones were obtained after limiting dilution. The pcDNA3.1 vector encoding Myc-hMcl-1 was obtained from Professor J Borst (Netherlands Cancer Institute). After digestion with BamH1 and Xba the product was inserted into the BamH1 and SnaB1 blunt-ended sites of the LZRS-IRES-GFP vector, resulting in LZRS-Myc-hMcl-1-IRES-GFP. ) were washed in PBS prior to fixation in 4% formaldehyde for 5 min at room temperature. Cells were washed in PBS and incubated in the presence of 1 mg/ml of anti-Bax (Ab-6, clone 6A7; Calbiochem) or anti-Bak (Ab-1; Calbiochem), diluted in permeabilization buffer (0.5% BSA þ 500 mg/ml digitonin in PBS) for 30 min at room temperature. Cells were washed in PBA (PBS þ 0.2% BSA þ 0.02% NaN 3 ) and incubated with goat anti-mouse PE-conjugated secondary antibody (Jackson ImmunoResearch Europe Ltd., Suffolk, England), diluted 1/200 in permeabilization buffer for 30 min at room temperature. Cells were washed with PBA, re-suspended in PBS and analyzed using the FACS.
Western blotting and IP. Cell lysates for western blotting were separated by 13% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by western blotting as described previously. 23 Blots were probed with the following antisera: monoclonal anti-Mcl-1 (BD Pharmingen), monoclonal anti-Bax (BD Pharmingen), Bak monoclonal antibody (mAb) (Upstate Biotechnology, Inc. Lake Placid, NY, USA), monoclonal anti-Bim (Figures 2 and 5a ; Chemicon, Temecula, CA, USA), polyclonal anti-Bim (Figures 3Ac and 5b ; Nventa, San Diego, CA, USA) monoclonal anti-Noxa from Imgenex (San Diego, CA, USA), polyclonal anti-Bcl-2 (Alexis Biochemicals), polyclonal cleaved caspase-3 (Asp175) antibody, polyclonal anti-p44/42-MAP Kinase (Cell signaling Technology Inc., Danvers, MA, USA) antibody and antiserum to b-actin was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
For IP of Mcl-1, 50 Â 10 6 cells were washed two times in ice-cold PBS (supplemented with 10 mM Na 3 VO 4 ) and lysed in 500 ml ice-cold Triton X-100 lysis buffer (1% Triton X-100, 20 mM Tris-Cl (pH ¼ 7.4), 135 mM NaCl, 1.5 mM MgCl 2 , 10% Glycerol, 2 mg/ml leupeptin, 1 mM PMSF and 2 mg/ml Trypsin inhibitor). Whole cell lysates were precleared with normal rabbit serum precoupled to protein Asepharose and incubated for 3 h with 5 mg polyclonal anti-Mcl-1 (BD Pharmingen) precoupled to protein A-sepharose. Beads were pelleted, washed six times with lysis buffer and boiled in SDS sample buffer, and further processed for western blotting.
CHAPS lysates were used in certain experiments to avoid detergent-induced conformational changes of Bax, 30 by lysing 50 Â 10 6 cells (for IP) or 15 Â 10 6 cells (for western blot) for 30 min on ice in lysis buffer (1% 3[(3-cholamidopropyl)dimethylammonio]-propane-sulfonic acid (CHAPS), 20 mM Tris-Cl (pH ¼ 7.4), 135 mM NaCl, 1.5 mM MgCl 2 ,10% glycerol, 1 mM EGTA, 2 mM Na 3 VO 4 , 10 mM NaF, 2 mg/ml leupeptin, 1 mM PMSF, 0.1 mM TLCK and 2 mg/ml Trypsin inhibitor). After centrifugation (15 min; 13 000 Â g; 41C), the supernatant was used for IP or as 'CHAPS soluble fraction' on western blot. Pellets were solubilized in SDS sample buffer and used in western blotting as the 'CHAPS insoluble fraction'. IP of Bim (monoclonal anti-Bim (Chemicon)) was performed as described above in 500 ml icecold CHAPS and lysates were precleared with normal rat serum precoupled to protein G-sepharose.
Immunocytochemistry and confocal analysis. B-CLL cells were incubated with 200 nM MitoTracker for 24 h at 371C and treated as described above (intracellular flow cytometry procedure). Cells (1 Â 10 6 ) were re-suspended in 25 ml vectashield (Hardset with DAPI; Vector Laboratories, CA, USA) and were spotted on coverslips. Images were independently captured by confocal laser microscopy (model TCS 4D, Leica, Heidelberg, Germany) at the wavelengths 488 and 594 nm lines of the krypton/argon laser used for the excitation of FITC and MitoTracker (Alexa594), respectively. Excitation of DAPI was by 594 nm.
Statistical analyses. The Student's t-test was used for analysis of differences between two groups. Po0.01 were considered statistically significant.
